Objective: To clarify the role of the pulmonary artery catheter in the intensive care unit.
F
or almost 40 years, the pulmonary artery catheter (PAC) has been considered a valued tool in the acutely ill patient to provide information on three key variables: intrathoracic intravascular pressures, cardiac output, and mixed venous oxygen saturation (SvO 2 ). The PAC allows the accurate measurement of these variables, which cannot be reliably obtained by clinical examination alone (1) , and can monitor them (almost) continuously. This comprehensive evaluation of the cardiovascular system has enabled clinicians to learn about and understand pathophysiological derangements and the response of these derangements to therapy. Despite these valuable attributes, over the last 10 yrs the PAC has been under attack (2) .
In a recent article, Wiener and Welch (3) added fuel to the PAC debate and may have caused unnecessary harm. These authors reported decreased PAC use in the United States, based on a retrospective review of changing practice patterns in a limited number of hospitals. Their sample excluded specific patient groups for whom the PAC is often used (e.g., patients undergoing cardiac surgery). Nevertheless, this report is consistent with a global sense of decreased PAC use in modern intensive care units and is consistent with previous observations (4). Although the cause for the decline in the usage of the PAC was not addressed in their study, Wiener and Welch (3) speculated that lack of efficacy was the primary reason for their observed findings. However, to infer causality from these data is questionable; other factors could have contributed, including a better understanding of the underlying pathophysiological alterations and major advances in the development of less invasive techniques, including echocardiography. Undoubtedly, the need to use the PAC for assessment of cardiovascular function has markedly reduced, but to claim that the decline in PAC use reflects failure of the technology to deliver on its promise is incorrect.
If we apply the argument that there is a lack of evidence showing a mortality reduction with PAC use, then practically every monitoring technique used in critical care should be abandoned (5) . We must be careful not to throw the baby out with the bathwater. Indeed, the authors of this recent article (3) and the accompanying editorial (6) make strong statements indicting the PAC and those who continue to rely on it. The authors (3) were surprised that teaching hospitals were more likely to use the PAC and further wrote "one would hope that the evidence showing no mortality reduction with this invasive procedure would disseminate rapidly in academic centers, resulting in lower than average rates of use." This statement is not supported by data and may detrimentally influence critical care practice. We are concerned that in both articles (3, 6) , the authors' statements are only opinions and as such may have a negative impact on the use of the PAC in patients in whom it may, in fact, provide useful information. Decreased use of the PAC does not necessarily equate to a lack of need to use it. Without question, the PAC was overused in the past, for a number of reasons, even including financial incentives (7) . This may be less true in Europe than in the United States, especially if one compares European data with those of the study by Connors et al. (2) (Fig. 1) . However, the PAC is used more sparingly everywhere than in the past as we try to limit its use to those patients who are most likely to benefit. Nevertheless, many more data (on mortality and/or morbidity) are necessary before we can conclude that the PAC should be abandoned.
Several prospective, randomized clinical trials (8 -11) have indicated that using a PAC does not influence outcomes, i.e., it is neither inherently dangerous nor beneficial. The interpretation of these studies is made difficult by their design. As investigators may still prefer to insert a PAC when they are convinced it may help, only those patients for whom there is equipoise, i.e., when the clinician feels uncertain about the beneficial aspects, can be randomized. Thus, in these studies (8 -11) , only a fraction of patients considered were actually enrolled and randomized, creating a significant treatment bias. In the Acute Respiratory Distress Syndrome network trial (11) patients were only included 36 hours after admission, at a time when further invasive monitoring may not be useful.
There are many prospective randomized clinical trials demonstrating no survival benefit attributable to the use of any monitoring device in acutely ill patients (5) . A recent prospective clinical trial on early goal-directed therapy showed that hemodynamic monitoring-guided resuscitation, if performed early, may improve outcome (12) . Nevertheless, even this trial did not demonstrate that a specific device (i.e., central venous oxygen saturation [ScvO 2 ] monitoring) was the key factor in improved outcome. The same applies to noninvasive monitoring. Pulse oximetry has been tested and not been found to improve outcomes (13) ; yet it continues to be universally used. Recent data do support the use of a targeted threshold oxygen delivery index (DO 2 I) in high risk surgery patients (preoptimization) to reduce mortality, morbidity, and length of stay. Clearly, newer monitoring devices including esophageal Doppler and arterial pulse contour analyses can be used to measure cardiac output. However, none measures SvO 2 nor can simultaneously assess intrathoracic vascular pressure, factors that may determine treatment options. Still, in the patient without pulmonary vascular pathology and absence of circulatory shock, these alternative monitoring techniques can drive effective protocols and target resuscitation goals as well as the PAC in the perioperative setting.
Should we limit the definition of benefit of a diagnostic test only to mortality reduction or are accurate diagnoses or treatment changes sufficient justification for their continued use? Diagnostic tests or monitoring procedures do not always decrease mortality. Many disorders diagnosed by computed tomography or magnetic resonance imaging are not amenable to treatment, but physicians will not stop performing scans because there is no therapy or outcome benefit. Should all these techniques be abandoned pending "hard" evidence from randomized clinical trials to prove outcome benefit? Clearly, diagnostic tests and monitoring procedures are not judged solely on the basis of changes in mortality and the PAC should not be treated differently. In comparison with other monitoring techniques, the PAC has undergone an unusually detailed evaluation. The lack of decreased mortality rates in the studies performed to date does not detract from the PAC as a diagnostic and monitoring tool. This is particularly true in the absence of any evidence that any alternative monitoring technique does improve survival.
Clearly, the PAC is indicated only in patients with complex problems or in whom important data elements are only attainable from its use. Some may argue that improving application requires therapeutic protocols. However, the application of invasive monitoring data is very complex and is not easily included in therapeutic protocols that are applicable across heterogeneous populations of acutely ill patients. Applications are more complex than "give fluids when the occlusion pressure is low and furosemide when it is high." Hemodynamic management is made complex by two realities. First, adequacy is not synonymous with "normality"-a high cardiac output and a low systemic vascular resistance may represent an appropriate response to sepsis and other inflammatory states; a low SvO 2 is expected in anemia and during exercise in healthy individuals. Second, correct application must integrate several variables and the reality may be more complex than initially thought. As an example, interpreting cardiac output in conjunction with occlusion pressure is not sufficient to assess cardiovascular sufficiency, one needs to include SvO 2 in the decision algorithm. Likewise the interpretation of SvO 2 is complex (14) and the maintenance of SvO 2 at normal levels in all critically ill patients once organ injury has developed may not improve outcomes (15) . Right ventricular failure in intensive care unit patients can be best monitored by a PAC (16) .
If we consider that the evidence supports a lack of benefit associated with the use of the PAC, how likely is it that less invasive monitoring systems will result in better outcomes? We fear a nihilistic approach. Unfortunately, the central venous pressure does not reliably reflect leftsided filling pressures nor predict volume responsiveness, less invasive measurements of cardiac output are often approximate (17) , and ScvO 2 is not a reliable reflection of SvO 2 (18) . It may be that actually there is no need to monitor hemodynamics as closely (or as invasively) as previously thought. Thus, we must not rush to substitute one technique for monitoring, now under question, with another device, simply because it is new and less invasive.
In fact, the lack of benefit from the use of hemodynamic variables raises serious concerns for current practice, because there can be only two interpretations: One is that the use of the PAC does not influence therapy (and, thus, cannot influence outcomes); the other is that it does influence therapy but that the changes in therapy do not improve outcome (i.e., our interventions are ineffective).
Taking the second scenario first, it seems unlikely that all intensive care unit interventions are useless, because there are a number of studies indicating that the intervention of an intensivist can in- Figure 1 . Frequency of use of the pulmonary artery catheter in the Connors study (during first 24 hrs of intensive care unit stay) in the United States (2) and in two epidemiologic studies in Europe, European Prevalence of Infection in Intensive Care (EPIC) (a 1-day point prevalence study) and Sepsis Occurrence in Acutely Ill Patients (SOAP) (any time during the intensive care unit stay) (24, 25) . Each study included a mixture of several thousand patients with various (medical and surgical) diagnoses.
deed positively influence outcomes (19) . Therefore, if our interventions are helpful, perhaps it is the way in which PAC findings are interpreted and used which is inadequate. Although there is some evidence that PAC use can influence patient management (20) , this may not be sufficient. Again, no monitoring device will improve outcome by itself. Only by guiding interventions can improved outcomes be achieved. Is it inadequate training in interpretation of the information obtained from the PAC that has led to the negative clinical trials? Possibly, but it is difficult to develop PAC-guided treatment protocols that are applicable across a heterogeneous population of acutely ill patients with complex comorbidities.
Rather than proposing an indictment of invasive hemodynamic monitoring, we suggest that we need to revisit the basics of hemodynamic management and reassess the way in which the PAC is used. It is intriguing to speculate that the decreased use of the PAC may lead to more errors and complications as staff become less familiar with its use, reinforcing the importance of adequate and continued training. Before PAC insertion, it is important to ask how the newly obtained information may influence the patient's management. There is no justification for invasive monitoring if there is little likelihood of deriving benefit from the information obtained.
Once a PAC is in place, one should insist on a strict three step process: Designing global protocols to guide therapy for every patient is a difficult task. This opinion is supported by studies mentioned above that documented better outcome in the centers that had the largest experience with the PAC (8, 22) . Even without a study demonstrating an improved outcome with PAC use, we believe that the PAC still has an important role in the diagnosis of clinical disorders and the monitoring of therapy, as PAC use has been shown to be safe. The PAC should be used wisely, only when indicated (7, 14, 23) . The PAC, like other diagnostic tests such as computed tomography and magnetic resonance imaging, must be used with clinical acumen; proper hemodynamic management requires a competent doctor at the bedside to integrate the individual factors present in each patient into a patient-specific management package. If a properly trained physician believes that invasive hemodynamic data are necessary for the management of a specific patient, then the use of the PAC is justified in that patient. Let us concentrate our efforts on the training of such doctors to utilize PACs more wisely. That PAC use is highest in teaching hospitals suggests that this message is still being heard. It is sometimes difficult in medicine to know whether we are embarking on a new era or just witnessing the swing of a pendulum.
